Erick Aybar settled way too cheap

16 Comments

More power to him if Erick Aybar loves Southern California and didn’t want to play anywhere else. He still should have done better than $35 million for four years in his new extension with the Angels.

$8.75 million per year is less than Julio Lugo got in his four-year deal with the Red Sox six years ago. It’s less than a well past his prime Edgar Renteria got from the Giants in a two-year deal for 2009-10. It’s barely more than Cristian Guzman earned in 2009-10.

And in case no one has noticed, the price tags have generally gone up since then. Aybar’s only rival at shortstop in free agency this winter would have been Stephen Drew, and at this point, there’s no telling if Drew is going to be a viable long-term shortstop after last year’s ankle injury. It’s possible no other starting shortstops will hit free agency this winter: Jhonny Peralta’s option is almost certain to be picked up by the Tigers, and Jason Bartlett and Alex Gonzalez both have 2013 options that figure to vest if they stay healthy.

Aybar may not be thought of as a star, but he certainly ranks among the game’s top 10 shortstops with his plus glove and .695 career OPS. Hitting free agency at age 29, he probably would have gotten $50 million for five years as a minimum. Instead, he settled for $35 million and didn’t even get no-trade protection in the bargain. Angels fans should be thrilled.

MLB, union resume blood testing after pandemic, lockout

Scott Taetsch-USA TODAY Sports
1 Comment

NEW YORK – In the first acknowledgment that MLB and the players’ association resumed blood testing for human growth hormone, the organizations said none of the 1,027 samples taken during the 2022 season tested positive.

HGH testing stopped in 2021 because of the COVID-19 pandemic. Testing also was halted during the 99-day lockout that ended in mid-March, and there were supply chain issues due to COVID-19 and additional caution in testing due to coronavirus protocols.

The annual public report is issued by Thomas M. Martin, independent program administrator of MLB’s joint drug prevention and treatment program. In an announcement accompanying Thursday’s report, MLB and the union said test processing is moving form the INRS Laboratory in Quebec, Canada, to the UCLA Laboratory in California.

MLB tests for HGH using dried blood spot testing, which was a change that was agreed to during bargaining last winter. There were far fewer samples taken in 2022 compared to 2019, when there were 2,287 samples were collected – none positive.

Beyond HGH testing, 9,011 urine samples were collected in the year ending with the 2022 World Series, up from 8,436 in the previous year but down from 9,332 in 2019. And therapeutic use exemptions for attention deficit hyperactivity disorder dropped for the ninth straight year, with just 72 exemptions in 2022.

Overall, the league issued six suspensions in 2022 for performance-enhancing substances: three for Boldenone (outfielder/first baseman Danny Santana, pitcher Richard Rodriguez and infielder Jose Rondon, all free agents, for 80 games apiece); one each for Clomiphene (Milwaukee catcher Pedro Severino for 80 games), Clostebol (San Diego shortstop Fernando Tatis Jr. for 80 games) and Stanozolol (Milwaukee pitcher J.C. Mejia for 80 games).

There was an additional positive test for the banned stimulant Clobenzorex. A first positive test for a banned stimulant results in follow-up testing with no suspension.